지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 346 - 355 (10page)
이용수
초록· 키워드
오류제보하기
Background: Combined therapy with alendronate and calcitriol may have additive effects on bone density. An observational study was performed to evaluate the efficacy and safety of Maxmarvil, a combinative agent of alendronate (5mg) and calcitriol (0.5 μg), and to identify factors associated with efficacy.
Methods: A total of 568 postmenopausal women with osteoporosis were enrolled by family physicians in 12 hospitals.
The study subjects took Maxmarvil daily for 12 months. Questionnaires about baseline characteristics, socioeconomic status, and daily calcium intake were completed at the first visit. Adverse events were recorded every 3 months and bone mineral density (BMD) in the lumbar spine was measured using dual-energy X-ray absorptiometry at baseline and after 12 months. We evaluated the efficacy and safety of Maxmarvil, and the factors related to BMD improvement.
Results: A total of 370 patients were included in final analysis. The median BMD was 0.81 ± 0.12 g/cm2 at pre-treatment and 0.84 ± 0.13 g/cm2 after one year. The average BMD improvement was 3.4% ± 6.4% (P < 0.05), and 167 (45.1%) patients showed improvement. Factors associated with improved BMD were continuation of treatment (odds ratio [OR], 2.41; 95%confidence interval [CI], 1.15 to 5.07) and good compliance (OR, 2.54; 95% CI, 1.29 to 5.00). Adverse events were reported by 35 of the 568 patients, with the most common being abdominal pain and dyspepsia.
Conclusion: Maxmarvil was found to be safe, well tolerated and effective in osteoporosis treatment. Continuation of treatment and good compliance were the factors associated with efficacy.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Bone HG / 2004 / Ten years’ experience with alendronate for osteoporosis in postmenopausal women / N Engl J Med 350 : 1189 ~ 1199
Cranney A / 2002 / Meta-analyses of therapies for postmenopausal osteoporosis: II. Meta-analysis of alendronate for the treatment of postmenopausal women / Endocr Rev 23 : 50
Emaus N / 2009 / Bone mineral density at the hip in Norwegian women and men--prevalence of osteoporosis depends on chosen references: the Tromso Study / Eur J Epidemiol 24 :
Frediani B / 1998 / Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: two years of continuous tre
Harris ST / 1999 / Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebra
Cranney A / 2002 / Meta-analyses of therapies for postmenopausal osteoporosis: II. Meta-analysis of alendronate for the treatment of postmenopausal women / Endocr Rev 23 : 50
Emaus N / 2009 / Bone mineral density at the hip in Norwegian women and men--prevalence of osteoporosis depends on chosen references: the Tromso Study / Eur J Epidemiol 24 :
Frediani B / 1998 / Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: two years of continuous tre
Harris ST / 1999 / Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebra
이 논문의 저자 정보
최근 본 자료
댓글(0)
0